CLAIMS

1. An antibody, or an antigen-binding fragment thereof, which binds specifically to Ara h 2 (Arachis hypogaea allergen 2).

2. The antibody, or an antigen-binding fragment thereof, according to claim 1, wherein the antibody or the antigen-binding fragment thereof, further binds specifically to Ara h 3 or to Ara h 6.

3. The antibody, or an antigen-binding fragment thereof, according to claim 1 or 2, wherein the antibody, or the antigen-binding fragment thereof, comprises a CDRH1 having at least 70% identity to SEQ ID NO: 1, a CDRH2 having at least 70% identity to SEQ ID NO: 2, a CDRH3 having at least 70% identity to SEQ ID NO: 3, a CDRL1 having at least 70% identity to SEQ ID NO: 4, a CDRL2 having at least 70% identity to SEQ ID NO: 5, and a CDRL3 having at least 70% identity to SEQ ID NO: 6.

4. The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, comprises a CDRH1 according to SEQ ID NO: 1, a CDRH2 according to SEQ ID NO: 2, a CDRH3 according to SEQ ID NO: 3, a CDRL1 according to SEQ ID NO: 4, a CDRL2 according to SEQ ID NO: 5, and a CDRL3 according to SEQ ID NO: 6.

5. The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, comprises a VH having at least 70% identity to any one of SEQ ID NOs 7, 44 and 45; and a VL having at least 70% identity to any one of SEQ ID NOs 8, 46, 47, 48 and 49.

6. The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, comprises a VH according to any one of SEQ ID NOs 7, 44 and 45; and a VL according to any one of SEQ ID NOs 8, 46, 47, 48 and 49.

7. The antibody, or an antigen-binding fragment thereof, according to claim 1 or 2, wherein the antibody, or the antigen-binding fragment thereof, comprises a CDRH1 having at least 70% identity to SEQ ID NO: 9, a CDRH2 having at least 70% identity to SEQ ID NO: 10, a CDRH3 having at least 70% identity to SEQ ID NO: 11, a CDRL1 having at least 70% identity to SEQ ID NO: 12, a CDRL2 having at least 70% identity to SEQ ID NO: 13, and a CDRL3 having at least 70% identity to SEQ ID NO: 14.

8. The antibody, or an antigen-binding fragment thereof, according to any one of claims 1, 2 and 7, wherein the antibody, or the antigen-binding fragment thereof, comprises a CDRH1 according to SEQ ID NO: 9, a CDRH2 according to SEQ ID NO: 10, a CDRH3 according to SEQ ID NO: 11, a CDRL1 according to SEQ ID NO: 12, a CDRL2 according to SEQ ID NO: 13, and a CDRL3 according to SEQ ID NO: 14.

9. The antibody, or an antigen-binding fragment thereof, according to any one of claims 1, 2, 7 and 8, wherein the antibody, or the antigen-binding fragment thereof, comprises a VH having at least 70% identity to any one of SEQ ID NOs 15, 37 and 38; and a VL having at least 70% identity to any one of SEQ ID NOs 16, 39 and 40.

10. The antibody, or an antigen-binding fragment thereof, according to any one of claims 1, 2 and 7 – 9, wherein the antibody, or the antigen-binding fragment thereof, comprises a VH according to any one of SEQ ID NOs 15, 37 and 38; and a VL according to any one of SEQ ID NOs 16, 39 and 40.

11. The antibody, or an antigen-binding fragment thereof, according to claim 1 or 2, wherein the antibody, or the antigen-binding fragment thereof, comprises a CDRH1 having at least 70% identity to SEQ ID NO: 17, a CDRH2 having at least 70% identity to SEQ ID NO: 18, a CDRH3 having at least 70% identity to SEQ ID NO: 51, a CDRL1 having at least 70% identity to SEQ ID NO: 20, a CDRL2 having at least 70% identity to SEQ ID NO: 21, and a CDRL3 having at least 70% identity to SEQ ID NO: 22.

12. The antibody, or an antigen-binding fragment thereof, according to any one of claims 1, 2 and 11, wherein the antibody, or the antigen-binding fragment thereof, comprises a CDRH1 according to SEQ ID NO: 17, a CDRH2 according to SEQ ID NO: 18, a CDRH3 according to SEQ

ID NO: 51, a CDRL1 according to SEQ ID NO: 20, a CDRL2 according to SEQ ID NO: 21, and a CDRL3 according to SEQ ID NO: 22.

13. The antibody, or an antigen-binding fragment thereof, according to any one of claims 1, 2, 11 and 12, wherein the antibody, or the antigen-binding fragment thereof, comprises a VH having at least 70% identity to SEQ ID NO: 53; and a VL having at least 70% identity to any one of SEQ ID NOs 24, 42 and 43.

14. The antibody, or an antigen-binding fragment thereof, according to any one of claims 1, 2 and 11 – 13, wherein the antibody, or the antigen-binding fragment thereof, comprises a VH according to SEQ ID NO: 53; and a VL according to any one of SEQ ID NOs 24, 42 and 43.

15. The antibody, or an antigen-binding fragment thereof, according to claim 1 or 2, wherein the antibody, or the antigen-binding fragment thereof, comprises a VH having at least 70% identity to any one of SEQ ID NOs 41, 50 and 53; and a VL having at least 70% identity to SEQ ID NO: 42 or 43.

16. The antibody, or an antigen-binding fragment thereof, according to claim 15, wherein the antibody, or the antigen-binding fragment thereof, comprises a VH according to any one of SEQ ID NOs 41, 50 and 53; and a VL according to SEQ ID NO: 42 or 43.

17. The antibody, or an antigen-binding fragment thereof, according to claim 1 or 2, wherein the antibody, or the antigen-binding fragment thereof, comprises a CDRH1 having at least 70% identity to SEQ ID NO: 25, a CDRH2 having at least 70% identity to SEQ ID NO: 26, a CDRH3 having at least 70% identity to SEQ ID NO: 27, a CDRL1 having at least 70% identity to SEQ ID NO: 28, a CDRL2 having at least 70% identity to SEQ ID NO: 52, and a CDRL3 having at least 70% identity to SEQ ID NO: 30.

18. The antibody, or an antigen-binding fragment thereof, according to any one of claims 1, 2 and 17, wherein the antibody, or the antigen-binding fragment thereof, comprises a CDRH1 according to SEQ ID NO: 25, a CDRH2 according to SEQ ID NO: 26, a CDRH3 according to SEQ ID NO: 27, a CDRL1 according to SEQ ID NO: 28, a CDRL2 according to SEQ ID NO: 52, and a CDRL3 according to SEQ ID NO: 30.

19. The antibody, or an antigen-binding fragment thereof, according to any one of claims 1, 2, 17 and 18, wherein the antibody, or the antigen-binding fragment thereof, comprises a VH having at least 70% identity to any one of SEQ ID NOs 31, 33 and 34; and a VL having at least 70% identity to SEQ ID NO: 54.

20. The antibody, or an antigen-binding fragment thereof, according to any one of claims 1, 2 and 17 – 19, wherein the antibody, or the antigen-binding fragment thereof, comprises a VH according to any one of SEQ ID NOs 31, 33 and 34; and a VL according to SEQ ID NO: 54.

21. The antibody, or an antigen-binding fragment thereof, according to claim 1 or 2, wherein the antibody, or the antigen-binding fragment thereof, comprises a VH having at least 70% identity to SEQ ID NO: 33 or 34; and a VL having at least 70% identity to any one of SEQ ID NOs 35, 36 and 54.

22. The antibody, or an antigen-binding fragment thereof, according to claim 21, wherein the antibody, or the antigen-binding fragment thereof, comprises a VH according to SEQ ID NO: 33 or 34; and a VL according to any one of SEQ ID NOs 35, 36 and 54.

23. The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the CDRs or the variable regions of the antibody, or the antigen-binding fragment thereof, are human or are derived from human CDR or variable region sequences.

24. The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, is a human antibody.

25. The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, is a monoclonal antibody.

26. The antibody according to any one according to the previous claims, wherein the antibody comprises an Fc moiety.

27. The antibody according to any one of the previous claims, wherein the antibody is of the IgG or IgA type.

28. The antibody according to claim 27, wherein the antibody is of the IgG1 or IgG4 type.

29. The antibody according to any one according to the previous claims, wherein the variable regions or the CDRs are derived from an IgE antibody and grafted in a scaffold of an IgG or IgA antibody.

30. The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, is purified.

31. The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, is a single-chain antibody.

32. The antibody, or an antigen-binding fragment thereof, according to claim 24, wherein the antibody, or the antigen-binding fragment thereof, is an scFv.

33. The antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 23, wherein the antibody, or the antigen-binding fragment thereof, is selected from Fab, Fab', F(ab')2 and Fv.

34. The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, is a multispecific antibody or a multispecific antigen-binding fragment.

35. The antibody, or an antigen-binding fragment thereof, according to claim 34, wherein the antibody, or the antigen-binding fragment thereof, binds to distinct, non-overlapping epitopes of Ara h 2.

36. The antibody, or an antigen-binding fragment thereof, according to claim 34, wherein the antibody, or the antigen-binding fragment thereof, comprises at least two of the following:

(i) an antigen-binding site comprising (a) the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 sequences and/or (b) the VH and VL sequences as defined in any one of claims 3 to 6;

(ii) an antigen-binding site comprising (a) the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 sequences and/or (b) the VH and VL sequences as defined in any one of claims 7 to 10;

(iii) an antigen-binding site comprising (a) the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 sequences and/or (b) the VH and VL sequences as defined in any one of claims 11 to 16;

(iv) an antigen-binding site comprising (a) the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 sequences and/or (b) the VH and VL sequences as defined in any one of claims 17 to 22.

37. A multispecific antibody, or a multispecific antigen-binding fragment, which binds to distinct, non-overlapping epitopes of Ara h 2, wherein the antibody, or the antigen-binding fragment, comprises at least two of the following:

(i) an antigen-binding site comprising a CDRH1 having at least 70% identity to SEQ ID NO: 1, a CDRH2 having at least 70% identity to SEQ ID NO: 2, a CDRH3 having at least 70% identity to SEQ ID NO: 3, a CDRL1 having at least 70% identity to SEQ ID NO: 4, a CDRL2 having at least 70% identity to SEQ ID NO: 5, and a CDRL3 having at least 70% identity to SEQ ID NO: 6;

(ii) an antigen-binding site comprising a CDRH1 having at least 70% identity to SEQ ID NO: 9, a CDRH2 having at least 70% identity to SEQ ID NO: 10, a CDRH3 having at least 70% identity to SEQ ID NO: 11, a CDRL1 having at least 70% identity to SEQ ID NO: 12, a CDRL2 having at least 70% identity to SEQ ID NO: 13, and a CDRL3 having at least 70% identity to SEQ ID NO: 14;

(iii) an antigen-binding site comprising a CDRH1 having at least 70% identity to according to SEQ ID NO: 17, a CDRH2 having at least 70% identity to SEQ ID NO: 18, a CDRH3 having at least 70% identity to SEQ ID NO: 19 or 51, a CDRL1 having at least 70% identity to SEQ ID NO: 20, a CDRL2 having at least 70% identity to SEQ ID NO: 21, and a CDRL3 having at least 70% identity to SEQ ID NO: 22;

(iv) an antigen-binding site comprising a CDRH1 having at least 70% identity to SEQ ID NO: 25, a CDRH2 having at least 70% identity to SEQ ID NO: 26, a CDRH3 having at least

70% identity to SEQ ID NO: 27, a CDRL1 having at least 70% identity to SEQ ID NO: 28, a CDRL2 having at least 70% identity to SEQ ID NO: 29 or 52, and a CDRL3 having at least 70% identity to SEQ ID NO: 30.

38. The antibody, or the antigen-binding fragment according to claim 37, wherein the antibody, or the antigen-binding fragment, comprises at least two of the following:
    (i) an antigen-binding site comprising a CDRH1 according to SEQ ID NO: 1, a CDRH2 according to SEQ ID NO: 2, a CDRH3 according to SEQ ID NO: 3, a CDRL1 according to SEQ ID NO: 4, a CDRL2 according to SEQ ID NO: 5, and a CDRL3 according to SEQ ID NO: 6;
    (ii) an antigen-binding site comprising a CDRH1 according to SEQ ID NO: 9, a CDRH2 according to SEQ ID NO: 10, a CDRH3 according to SEQ ID NO: 11, a CDRL1 according to SEQ ID NO: 12, a CDRL2 according to SEQ ID NO: 13, and a CDRL3 according to SEQ ID NO: 14;
    (iii) an antigen-binding site comprising a CDRH1 according to according to SEQ ID NO: 17, a CDRH2 according to SEQ ID NO: 18, a CDRH3 according to SEQ ID NO: 19 or 51, a CDRL1 according to SEQ ID NO: 20, a CDRL2 according to SEQ ID NO: 21, and a CDRL3 according to SEQ ID NO: 22;
    (iv) an antigen-binding site comprising a CDRH1 according to SEQ ID NO: 25, a CDRH2 according to SEQ ID NO: 26, a CDRH3 according to SEQ ID NO: 27, a CDRL1 according to SEQ ID NO: 28, a CDRL2 according to SEQ ID NO: 29 or 52, and a CDRL3 according to SEQ ID NO: 30.

39. The antibody or the antigen-binding fragment according to claim 37 or 38, wherein the antibody, or the antigen-binding fragment, comprises at least two of the following:
    (i) an antigen-binding site comprising a VH having at least 70% identity to any one of SEQ ID NOs 7, 44 and 45; and a VL having at least 70% identity to any one of SEQ ID NOs 8, 46, 47, 48 and 49;
    (ii) an antigen-binding site comprising a VH having at least 70% identity to any one of SEQ ID NOs 15, 37 and 38; and a VL having at least 70% identity to any one of SEQ ID NOs 16, 39 and 40;

(iii) an antigen-binding site comprising a VH having at least 70% identity to any one of SEQ ID NOs 23, 41, 50 and 53; and a VL having at least 70% identity to any one of SEQ ID NOs 24, 42 and 43;

(iv) an antigen-binding site comprising a VH having at least 70% identity to any one of SEQ ID NOs 31, 33 and 34; and a VL having at least 70% identity to any one of SEQ ID NOs 32, 35, 36 and 54.

40. The antibody or the antigen-binding fragment according to any one of claims 37 – 39, wherein the antibody, or the antigen-binding fragment, comprises at least two of the following:

(i) an antigen-binding site comprising a VH according to any one of SEQ ID NOs 7, 44 and 45; and a VL according to any one of SEQ ID NOs 8, 46, 47, 48 and 49;

(ii) an antigen-binding site comprising a VH according to any one of SEQ ID NOs 15, 37 and 38; and a VL according to any one of SEQ ID NOs 16, 39 and 40;

(iii) an antigen-binding site comprising a VH according to any one of SEQ ID NOs 23, 41, 50 and 53; and a VL according to any one of SEQ ID NOs 24, 42 and 43;

(iv) an antigen-binding site comprising a VH according to any one of SEQ ID NOs 31, 33 and 34; and a VL according to any one of SEQ ID NOs 32, 35, 36 and 54.

41. The antibody or the antigen-binding fragment according to any one of claims 36 – 39, wherein the antibody, or the antigen-binding fragment, is trispecific and comprises three distinct antigen-binding sites selected from (i) – (iv).

42. The antibody or the antigen-binding fragment according to any one of claims 36 – 39, wherein the antibody, or the antigen-binding fragment, is tetraspecific and comprises the four distinct antigen-binding sites according to (i), (ii), (iii) and (iv).

43. The antibody or the antigen-binding fragment according to claim 3 or 4, wherein the CDRH1, CDRH2 and CDRH3 sequences are contained by a human variable light chain framework region VH chain selected from the group consisting of the amino acid sequences encoded by the genes IGHV1-18, IGHV1-2, IGHV1-24, IGHV1-3, IGHV1-45, IGHV1-46, IGHV1-58, IGHV1-69, IGHV1-69-2, IGHV1-69D, IGHV1-8, IGHV2-26, IGHV2-5, IGHV2-70, IGHV2-70D, IGHV3-11, IGHV3-13, IGHV3-15, IGHV3-20, IGHV3-21, IGHV3-23, IGHV3-23D, IGHV3-30, IGHV3-30-3,

IGHV3-30-5, IGHV3-33, IGHV3-35, IGHV3-43, IGHV3-43D, IGHV3-48, IGHV3-49, IGHV3-53, IGHV3-62, IGHV3-64, IGHV3-64D, IGHV3-66, IGHV3-7, IGHV3-72, IGHV3-73, IGHV3-74, IGHV3-9, IGHV3-NL1, IGHV4-28, IGHV4-30-1, IGHV4-30-2, IGHV4-30-4, IGHV4-31, IGHV4-34, and IGHV4-38-2.

44. The antibody or the antigen-binding fragment according to claim 3, 4 or 43, wherein the CDRL1, CDRL2 and CDRL3 sequences are contained by a human variable light chain framework region VL chain selected from the group consisting of the amino acid sequences encoded by the genes IGLV1-36, IGLV1-40, IGLV1-44, IGLV1-47, IGLV1-51, IGLV10-54, IGLV2-11, IGLV2-14, IGLV2-18, IGLV2-23, IGLV2-8, IGLV3-1, IGLV3-10, IGLV3-12, IGLV3-16, IGLV3-19, IGLV3-21, IGLV3-22, IGLV3-25, IGLV3-27, IGLV3-9, IGLV4-3, IGLV4-60, IGLV4-69, IGLV5-37, IGLV5-39, IGLV5-45, IGLV5-52, IGLV6-57, IGLV7-43, IGLV7-46, IGLV8-61, and IGLV9-49.

45. The antibody or the antigen-binding fragment according to claim 3, 4, or 43, wherein the CDRL1, CDRL2 and CDRL3 sequences are contained by a human variable light chain framework region VK chain selected from the group consisting of the amino acid sequences encoded by the genes IGKV1-12, IGKV1-13, IGKV1-16, IGKV1-17, IGKV1-27, IGKV1-33, IGKV1-39, IGKV1-5, IGKV1-6, IGKV1-8, IGKV1-9, IGKV1-NL1, IGKV1D-12, IGKV1D-13, IGKV1D-16, IGKV1D-17, IGKV1D-33, IGKV1D-39, IGKV1D-43, IGKV1D-8, IGKV2-24, IGKV2-28, IGKV2-29, IGKV2-30, IGKV2-40, IGKV2D-26, IGKV2D-28, IGKV2D-29, IGKV2D-30, IGKV2D-40, IGKV3-11, IGKV3-15, IGKV3-20, IGKV3D-11, IGKV3D-15, IGKV3D-20, IGKV3D-7, IGKV4-1, IGKV5-2, IGKV6-21, and IGKV6D-21.

46. The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims for use as a medicament.

47. The antibody, or an antigen-binding fragment thereof, for use according to claim 46 in prophylaxis or treatment of peanut allergy.

48. A nucleic acid molecule comprising a polynucleotide encoding the antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 45.

49. The nucleic acid molecule according to claim 48 comprising a nucleic acid sequence as set forth in any one of SEQ ID NOs 64 - 99; or a sequence variant thereof having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity.

50. A plurality of nucleic acid molecules encoding the antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 45, wherein each of the nucleic acid molecules comprises a polynucleotide encoding an immunoglobulin chain of the antibody, or an antigen-binding fragment thereof.

51. The combination of nucleic acid molecules according to claim 50 comprising a nucleic acid sequence as set forth in any one of SEQ ID NOs 64 - 99; or a sequence variant thereof having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity.

52. A vector comprising the nucleic acid molecule according to claim 48 or 49 or the plurality of nucleic acid molecules according to claim 50 or 51.

53. A plurality of vectors comprising the plurality of nucleic acid molecules according to claim 50 or 51.

54. A host cell expressing the antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 45, or comprising the vector according to claim 52 or the combination of vectors of claim 53.

55. A method for preparing the antibody, or an antigen-binding fragment thereof, according any one of claims 1 to 45, or immunoglobulin chain(s) thereof, said method comprising

(i) culturing the host cell according to claim 54; and

(ii) isolating the antibody or immunoglobulin chain(s) thereof from the culture.

56. A composition comprising the antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 45, the nucleic acid or the plurality of nucleic acids according to any one of claims 48 to 51, the vector or the plurality of vectors according to claim 52 or 53, or the cell according to claim 54.

57. The composition according to claim 56 further comprising a pharmaceutically acceptable excipient, diluent or carrier.

58. The composition according to claim 56 or 57, wherein the composition comprises at least two distinct antibodies, or antigen-binding fragments thereof, binding to distinct, non-overlapping epitopes of Ara h 2.

59. The composition according to claim 58, wherein the composition comprises at least two of the following:
    (i) the antibody, or the antigen-binding fragment thereof, according to any one of claims 3 to 6;
    (ii) the antibody, or the antigen-binding fragment thereof, according to any one of claims 7 to 10;
    (iii) the antibody, or the antigen-binding fragment thereof, according to any one of claims 11 to 16;
    (iv) the antibody, or the antigen-binding fragment thereof, according to any one of claims 17 to 22.

60. The composition according to claim 58 or 59 comprising (exactly) three or four distinct antibodies, or antigen-binding fragments, binding to distinct, non-overlapping epitopes of Ara h 2, wherein the (exactly) three or four distinct antibodies, or antigen-binding fragments, are preferably selected from (i) – (iv) of claim 59.

61. A composition comprising at least three distinct antibodies, or antigen-binding fragments thereof, wherein the three distinct antibodies or antigen-binding fragments bind to distinct, non-overlapping epitopes of Ara h 2, wherein the composition comprises at least three of the following:

(i) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 having at least 70% identity to SEQ ID NO: 1, a CDRH2 having at least 70% identity to SEQ ID NO: 2, a CDRH3 having at least 70% identity to SEQ ID NO: 3, a CDRL1 having at least 70% identity to SEQ ID NO: 4, a CDRL2 having at least 70% identity to SEQ ID NO: 5, and a CDRL3 having at least 70% identity to SEQ ID NO: 6;

(ii) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 having at least 70% identity to SEQ ID NO: 9, a CDRH2 having at least 70% identity to SEQ ID NO: 10, a CDRH3 having at least 70% identity to SEQ ID NO: 11, a CDRL1 having at least 70% identity to SEQ ID NO: 12, a CDRL2 having at least 70% identity to SEQ ID NO: 13, and a CDRL3 having at least 70% identity to SEQ ID NO: 14;

(iii) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 having at least 70% identity to according to SEQ ID NO: 17, a CDRH2 having at least 70% identity to SEQ ID NO: 18, a CDRH3 having at least 70% identity to SEQ ID NO: 19 or 51, a CDRL1 having at least 70% identity to SEQ ID NO: 20, a CDRL2 having at least 70% identity to SEQ ID NO: 21, and a CDRL3 having at least 70% identity to SEQ ID NO: 22;

(iv) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 having at least 70% identity to SEQ ID NO: 25, a CDRH2 having at least 70% identity to SEQ ID NO: 26, a CDRH3 having at least 70% identity to SEQ ID NO: 27, a CDRL1 having at least 70% identity to SEQ ID NO: 28, a CDRL2 having at least 70% identity to SEQ ID NO: 29 or 52, and a CDRL3 having at least 70% identity to SEQ ID NO: 30.

62. The composition according to claim 61, wherein the composition comprises at least three of the following:

(i) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 according to SEQ ID NO: 1, a CDRH2 according to SEQ ID NO: 2, a CDRH3 according to SEQ ID NO: 3, a CDRL1 according to SEQ ID NO: 4, a CDRL2 according to SEQ ID NO: 5, and a CDRL3 according to SEQ ID NO: 6;

(ii) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 according to SEQ ID NO: 9, a CDRH2 according to SEQ ID NO: 10, a CDRH3 according to SEQ ID NO: 11, a CDRL1 according to SEQ ID NO: 12, a CDRL2 according to SEQ ID NO: 13, and a CDRL3 according to SEQ ID NO: 14;

(iii) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 according to according to SEQ ID NO: 17, a CDRH2 according to SEQ ID NO: 18, a CDRH3

according to SEQ ID NO: 19 or 51, a CDRL1 according to SEQ ID NO: 20, a CDRL2 according to SEQ ID NO: 21, and a CDRL3 according to SEQ ID NO: 22;

(iv) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 according to SEQ ID NO: 25, a CDRH2 according to SEQ ID NO: 26, a CDRH3 according to SEQ ID NO: 27, a CDRL1 according to SEQ ID NO: 28, a CDRL2 according to SEQ ID NO: 29 or 52, and a CDRL3 according to SEQ ID NO: 30.

63. The composition according to claim 61 or 62, wherein the composition comprises at least three of the following:

(i) an antibody, or an antigen-binding fragment thereof, comprising a VH having at least 70% identity to any one of SEQ ID NOs 7, 44 and 45; and a VL having at least 70% identity to any one of SEQ ID NOs 8, 46, 47, 48 and 49;

(ii) an antibody, or an antigen-binding fragment thereof, comprising a VH having at least 70% identity to any one of SEQ ID NOs 15, 37 and 38; and a VL having at least 70% identity to any one of SEQ ID NOs 16, 39 and 40;

(iii) an antibody, or an antigen-binding fragment thereof, comprising a VH having at least 70% identity to any one of SEQ ID NOs 23, 41, 50 and 53; and a VL having at least 70% identity to any one of SEQ ID NOs 24, 42 and 43;

(iv) an antibody, or an antigen-binding fragment thereof, comprising a VH having at least 70% identity to any one of SEQ ID NOs 31, 33 and 34; and a VL having at least 70% identity to any one of SEQ ID NOs 32, 35, 36 and 54.

64. The composition according to any one of claims 61 – 63, wherein the composition comprises at least three of the following:

(i) an antibody, or an antigen-binding fragment thereof, comprising a VH according to any one of SEQ ID NOs 7, 44 and 45; and a VL according to any one of SEQ ID NOs 8, 46, 47, 48 and 49;

(ii) an antibody, or an antigen-binding fragment thereof, comprising a VH according to any one of SEQ ID NOs 15, 37 and 38; and a VL according to any one of SEQ ID NOs 16, 39 and 40;

(iii) an antibody, or an antigen-binding fragment thereof, comprising a VH according to any one of SEQ ID NOs 23, 41, 50 and 53; and a VL according to any one of SEQ ID NOs 24, 42 and 43;

(iv) an antibody, or an antigen-binding fragment thereof, comprising a VH according to any one of SEQ ID NOs 31, 33 and 34; and a VL according to any one of SEQ ID NOs 32, 35, 36 and 54.

65. The composition according to any one of claims 59 – 64, wherein the composition comprises the four distinct antibodies, or antigen-binding fragments, according to (i), (ii), (iii) and (iv).

66. The composition according to any one of claims 56 – 64, wherein the composition further comprises at least one additional agent useful for treating peanut allergy.

67. The composition according to claim 66, wherein the additional agent useful for treating peanut allergy is selected from the group consisting of: β-adrenergic agonists, epinephrine, antihistamine, corticosteroid, anti-IgE antibody, anti-IgE antibody binding fragment, peptide vaccine and further antibodies capable of binding to a peanut allergen.

68. The composition according to any one of claims 56 – 67, wherein the composition further comprises a peanut allergen, preferably selected from the group consisting of Ara h1, Ara h2, Ara h3 and Ara h6 or a mixture thereof.

69. A kit comprising one or more of
    (i) the antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 45;
    (ii) the nucleic acid molecule(s) according to any one of claims 48 to 51;
    (iii) the vector(s) according to claim 52 or 53;
    (iv) the cell according to claim 54; and/or
    (v) the composition according to any one of claims 56 to 68.

70. The kit according to claim 69, wherein the kit comprises
    (i) at least two distinct antibodies, or antigen-binding fragments thereof, according to any one of claims 1 to 45, which bind to distinct, non-overlapping epitopes of Ara h 2;
    (ii) nucleic acid molecule(s) encoding at least two distinct antibodies, or antigen-binding fragments thereof, according to any one of claims 1 to 45, which bind to distinct, non-overlapping epitopes of Ara h 2; or

(iii) composition(s) comprising (i) or (ii).

71. The kit according to claim 70 comprising three or four distinct antibodies, or antigen-binding fragments thereof, according to any one of claims 1 to 45, which bind to distinct, non-overlapping epitopes of Ara h 2; or nucleic acid(s) encoding said antibodies or compositions comprising said antibodies.

72. A kit comprising at least three distinct antibodies, or antigen-binding fragments thereof, wherein the three distinct antibodies or antigen-binding fragments bind to distinct, non-overlapping epitopes of Ara h 2, wherein the kit comprises at least three of the following:

(i) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 having at least 70% identity to SEQ ID NO: 1, a CDRH2 having at least 70% identity to SEQ ID NO: 2, a CDRH3 having at least 70% identity to SEQ ID NO: 3, a CDRL1 having at least 70% identity to SEQ ID NO: 4, a CDRL2 having at least 70% identity to SEQ ID NO: 5, and a CDRL3 having at least 70% identity to SEQ ID NO: 6;

(ii) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 having at least 70% identity to SEQ ID NO: 9, a CDRH2 having at least 70% identity to SEQ ID NO: 10, a CDRH3 having at least 70% identity to SEQ ID NO: 11, a CDRL1 having at least 70% identity to SEQ ID NO: 12, a CDRL2 having at least 70% identity to SEQ ID NO: 13, and a CDRL3 having at least 70% identity to SEQ ID NO: 14;

(iii) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 having at least 70% identity to according to SEQ ID NO: 17, a CDRH2 having at least 70% identity to SEQ ID NO: 18, a CDRH3 having at least 70% identity to SEQ ID NO: 19 or 51, a CDRL1 having at least 70% identity to SEQ ID NO: 20, a CDRL2 having at least 70% identity to SEQ ID NO: 21, and a CDRL3 having at least 70% identity to SEQ ID NO: 22;

(iv) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 having at least 70% identity to SEQ ID NO: 25, a CDRH2 having at least 70% identity to SEQ ID NO: 26, a CDRH3 having at least 70% identity to SEQ ID NO: 27, a CDRL1 having at least 70% identity to SEQ ID NO: 28, a CDRL2 having at least 70% identity to SEQ ID NO: 29 or 52, and a CDRL3 having at least 70% identity to SEQ ID NO: 30.

73. The kit according to claim 72, wherein the kit comprises at least three of the following:

(i) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 according to SEQ ID NO: 1, a CDRH2 according to SEQ ID NO: 2, a CDRH3 according to SEQ ID NO: 3, a CDRL1 according to SEQ ID NO: 4, a CDRL2 according to SEQ ID NO: 5, and a CDRL3 according to SEQ ID NO: 6;

(ii) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 according to SEQ ID NO: 9, a CDRH2 according to SEQ ID NO: 10, a CDRH3 according to SEQ ID NO: 11, a CDRL1 according to SEQ ID NO: 12, a CDRL2 according to SEQ ID NO: 13, and a CDRL3 according to SEQ ID NO: 14;

(iii) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 according to according to SEQ ID NO: 17, a CDRH2 according to SEQ ID NO: 18, a CDRH3 according to SEQ ID NO: 19 or 51, a CDRL1 according to SEQ ID NO: 20, a CDRL2 according to SEQ ID NO: 21, and a CDRL3 according to SEQ ID NO: 22;

(iv) an antibody, or an antigen-binding fragment thereof, comprising a CDRH1 according to SEQ ID NO: 25, a CDRH2 according to SEQ ID NO: 26, a CDRH3 according to SEQ ID NO: 27, a CDRL1 according to SEQ ID NO: 28, a CDRL2 according to SEQ ID NO: 29 or 52, and a CDRL3 according to SEQ ID NO: 30.

74. The kit according to claim 72 or 73, wherein the kit comprises at least three of the following:

(i) an antibody, or an antigen-binding fragment thereof, comprising a VH having at least 70% identity to any one of SEQ ID NOs 7, 44 and 45; and a VL having at least 70% identity to any one of SEQ ID NOs 8, 46, 47, 48 and 49;

(ii) an antibody, or an antigen-binding fragment thereof, comprising a VH having at least 70% identity to any one of SEQ ID NOs 15, 37 and 38; and a VL having at least 70% identity to any one of SEQ ID NOs 16, 39 and 40;

(iii) an antibody, or an antigen-binding fragment thereof, comprising a VH having at least 70% identity to any one of SEQ ID NOs 23, 41, 50 and 53; and a VL having at least 70% identity to any one of SEQ ID NOs 24, 42 and 43;

(iv) an antibody, or an antigen-binding fragment thereof, comprising a VH having at least 70% identity to any one of SEQ ID NOs 31, 33 and 34; and a VL having at least 70% identity to any one of SEQ ID NOs 32, 35, 36 and 54.

75. The kit according to any one of claims 72 – 74, wherein the kit comprises at least three of the following:

(i) an antibody, or an antigen-binding fragment thereof, comprising a VH according to any one of SEQ ID NOs 7, 44 and 45; and a VL according to any one of SEQ ID NOs 8, 46, 47, 48 and 49;

(ii) an antibody, or an antigen-binding fragment thereof, comprising a VH according to any one of SEQ ID NOs 15, 37 and 38; and a VL according to any one of SEQ ID NOs 16, 39 and 40;

(iii) an antibody, or an antigen-binding fragment thereof, comprising a VH according to any one of SEQ ID NOs 23, 41, 50 and 53; and a VL according to any one of SEQ ID NOs 24, 42 and 43;

(iv) an antibody, or an antigen-binding fragment thereof, comprising a VH according to any one of SEQ ID NOs 31, 33 and 34; and a VL according to any one of SEQ ID NOs 32, 35, 36 and 54.

76. The kit according to any one of claims 72 – 75, wherein the kit comprises the four distinct antibodies, or antigen-binding fragments, according to (i), (ii), (iii) and (iv).

77. The kit according to any one of claims 69 – 76, wherein the kit further comprises at least one additional agent useful for treating peanut allergy.

78. The kit according to any one of claims 69 – 77, wherein the kit further comprises a peanut allergen.

79. The antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 45, the nucleic acid or the plurality of nucleic acids according to any one of claims 48 to 51, the vector or the plurality of vectors according to claim 52 or 53, the cell according to claim 54, the composition according to any one of claims 56 to 68, or the kit according to any one of claims 69 to 78 for use as a medicament.

80. The antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 45, the nucleic acid or the plurality of nucleic acids according to any one of claims 48 to 51, the vector or the plurality of vectors according to claim 52 or 53, the cell according to claim 54, the composition according to any one of claims 56 to 68, or the kit according to any one of claims 69 to 78 for use in the prophylaxis or treatment of a peanut allergy.

81. The antibody, or the antigen-binding fragment thereof, the nucleic acid or the plurality of nucleic acids, the vector or the plurality of vectors, the cell, or the composition for use according to claim 80, wherein at least two, three or four distinct antibodies or antigen-binding fragments thereof, which bind to distinct non-overlapping epitopes of Ara h 2; or nucleic acid(s) or vector(s) encoding the distinct antibodies; or composition(s) comprising the distinct antibodies to be administered.

82. The antibody, or the antigen-binding fragment thereof, the nucleic acid or the plurality of nucleic acids, the vector or the plurality of vectors, the cell, or the composition for use according to claim 80 or 81, wherein the administration of the antibody, or the antigen-binding fragment thereof, the nucleic acid or the plurality of nucleic acids, the vector or the plurality of vectors, the cell, or the composition is combined with the administration of a peanut allergen, preferably selected from the group consisting of Ara h1, Ara h2, Ara h3 and Ara h6 or a mixture thereof..

83. The antibody, or the antigen-binding fragment thereof, or the composition for use according to claim 82, wherein the antibody, or the antigen-binding fragment thereof, or the composition is to be administered before or during a desensitization procedure with a peanut allergen.

84. Use of the antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 45, the composition according to any one of claims 56 to 68, or the kit according to any one of claims 69 to 78 in (*in-vitro*) diagnosis of a peanut allergy.

85. Use of the antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 45, according to any one of claims 56 to 68, or the kit according to any one of claims 69 to 78 in a method for detecting a peanut allergen.

86. Use of the antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 45, the nucleic acid or the plurality of nucleic acids according to any one of claims 48 to 51, the vector or the plurality of vectors according to claim 52 or 53, the cell according to claim 54, the composition according to any one of claims 56 to 68, or the kit according to

any one of claims 69 to 78 in the manufacture of a medicament for prophylaxis, treatment or attenuation of a peanut allergy.

87. Use of a therapeutically effective amount of the antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 45, the nucleic acid or the plurality of nucleic acids according to any one of claims 48 to 51, the vector or the plurality of vectors according to claim 52 or 53, the cell according to claim 54, the composition according to any one of claims 56 to 68, or the kit according to any one of claims 69 to 78, in the manufacture of a medicament for treating, ameliorating or reducing a peanut allergy, or lowering the risk of a peanut allergic or anaphylactic reaction, wherein said medicament is to be administered to a subject in need thereof.